About Myelodysplastic Syndrome (Myelodysplasia)
Myelodysplastic syndrome (MDS), also known as myelodysplasia, is a group of rare blood cancers that affect the development of blood cells in the bone marrow. In MDS, the bone marrow produces abnormal and immature blood cells that crowd out healthy white blood cells, red blood cells, and platelets. This condition is characterized by:
- Cytopenia: Lower than normal levels of blood cells.
- Morphological dysplasia: Abnormal cell appearance.
MDS can sometimes progress to acute myeloid leukemia (AML), a faster-growing type of cancer. Dysplasia can be observed in various cell types in the bone marrow, including:
- Erythroid cells: Red blood cell precursors.
- Myeloid lineage cells: White blood cell precursors.
- Megakaryocytes: Platelet precursors.
Recurrent cytogenetic abnormalities, such as chromosomal deletions or translocations, are often present in MDS. The risk of developing MDS can vary based on genetic factors and exposure to certain environmental factors.
Regular monitoring may be recommended for individuals without symptoms to assess disease progression.
The causes of MDS are related to abnormalities in the bone marrow and blood cells. MDS is characterized by ineffective hematopoiesis, where blood cells in the bone marrow do not mature properly. This can lead to cytopenia (low blood cell counts).
Non-modifiable risk factors for MDS (factors that a person cannot change or control) include:
- Age: The risk of MDS increases with older age
- Sex: Male sex assigned at birth are more likely to develop MDS compared to female sex assigned at birth
- Prior exposure to radiotherapy or chemotherapy
Modifiable risk factors for MDS (factors that a person can potentially change or control) include:
- Obesity
- Smoking
It's important to note that while these risk factors have been identified, the exact mechanisms by which they contribute to MDS are not fully understood.
If you have concerns about your risk factors or symptoms, it's always best to consult with a healthcare professional for personalized advice.
The most common early symptoms of MDS may not be noticeable in slow-growing types. However, as the condition progresses or reaches higher severity, the following symptoms may occur:
Early Symptoms:
- Fatigue
- Tiring easily
- Feeling generally unwell
- Fever
- Frequent infections
- Bruising or bleeding easily
Later Stage/Progression Symptoms:
- Anemia (low red blood cell count)
- Weakness
- Shortness of breath
- Paleness
- Easy or prolonged bleeding
- Weakened immune system leading to frequent infections
- Defective platelet levels affecting blood clotting ability
It is important to note that these symptoms can vary depending on the individual and the specific type and stage of MDS.
If you experience any of these symptoms, it is recommended to consult with a healthcare professional for an accurate diagnosis and appropriate management.
To diagnose MDS, the following examinations, tests, and procedures are commonly performed:
- Physical exam and health history: The healthcare provider will examine the body for general signs of health and inquire about past illnesses and treatments.
- Complete blood count (CBC) with differential: This involves drawing a blood sample to check the number of red blood cells, platelets, and white blood cells, as well as the amount of hemoglobin in the red blood cells.
- Peripheral blood smear: A sample of blood is examined for blast cells, white blood cell types, platelet count, and changes in the shape of blood cells.
- Imaging studies: X-rays, CT scans, or MRI scans may be performed to assess the presence of any masses or abnormalities in the body.
It is important to follow up with your healthcare provider if your symptoms worsen or change after the initial physical exam. They will review the results of these examinations, tests, and procedures to help determine a diagnosis and determine the severity of MDS.
The goals of treatment for MDS depend on several factors such as a person’s age, comorbidities, and prognostic risk. The main treatment goals for MDS are:
Correcting cytopenias: The primary aim is to address low blood cell counts, especially anemia. This can be achieved through various approaches, including:
- Supportive therapy: This involves blood transfusions of specific types of cells and antibiotic treatment for infections that may develop.
- Hematopoietic growth factors: These are immunotherapies currently under clinical investigation.
Delaying progression to acute myeloid leukemia (AML): MDS can evolve into AML in about 30% of cases. Treatment strategies to delay this transformation include:
- Chemotherapy: More aggressive forms of MDS may require chemotherapy, particularly if the disease progresses to AML.
- Bone marrow transplantation: This is an option for younger patients under the age of 55.
Prolonging survival and improving quality of life: Treatment approaches to achieve these goals include:
- Low-dose or intensive chemotherapy: Certain categories of MDS cases may benefit from chemotherapy.
- Vitamin therapy, steroids, and immunosuppressive agents: These supportive care measures can help manage symptoms and improve quality of life.
It's important to note that specific medication types and therapies may vary depending on individual patient characteristics and disease severity. Always consult with a healthcare professional for personalized advice.
Medication dosing may be affected by many factors. Check with your health care professional about dosing for your individual situation. Side effects can occur. Check with your health care professional or read the information provided with your medication for additional side effect information.